Pombiliti

(Cipaglucosidase alfa-atga)

Pombiliti

Drug updated on 1/4/2024

Dosage FormInjection (intravenous: 105 mg)
Drug ClassHydrolytic lysosomal glycogen-specific enzyme
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • POMBILITI is indicated, in combination with Opfolda, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT).

Product Monograph / Prescribing Information